Acadia Pharmaceuticals Q3 2026 Results: Net Income $53.5M, Down 25.4% YoY
ACADIA Pharmaceuticals reported strong revenue growth driven by its commercial products, NUPLAZID and DAYBUE, alongside disciplined management of operating expenses. The company continues to invest in its late-stage clinical pipeline while showing significant progress toward sustained profitability.
- Key figure
- Net income $53.5M · -25.4% YoY